PubMed Health⌕ Search

Biomedical subjects

M Nørgaard

Publications and source records attributed to M Nørgaard.

26 records · Page 2Linked to original sources
PubMed1988

Terodiline, emepronium bromide or placebo for treatment of female detrusor overactivity? A randomised, double-blind, cross-over study.

In a randomised, double-blind study, 20 women with idiopathic detrusor instability and associated symptoms were treated with terodiline 25 mg bd, placebo, and emepronium bromide 200 mg tds--each drug being given for 3 weeks with placebo as wash-out period before cross-over. The results were evaluated according to drug preference, frequency charts and elimination of detrusor instability on cystometry. Serum levels of both drugs were monitored as control of tablet intake. The preference for terodiline to placebo was statistically significant: 14/3 women (P less than 0.05), and the majority of women (12/4) preferred terodiline to emepronium. Terodiline also gave a small but significant reduction in 24 h micturition frequency and eliminated detrusor instability in almost 50% of the patients (P less than 0.05). Side effects were frequent but mild in all three treatment periods. It was concluded that terodiline offers an alternative in the treatment of female detrusor instability.

Adult↗
PubMed1986

Anthralin stick (Anthraderm) in the treatment of mosaic warts.

Thirty patients having mosaic warts of the soles for 2 years (range 3 months-6 years) were treated daily with a wax-based anthralin stick supplemented by weekly paring. Six patients dropped out, because they failed to appear for follow-up. Of the remaining patients 17/24 cleared, whereas the warts persisted in 7/24. Although the trial was an open study, this result can hardly be explained by placebo effect since mosaic warts are notoriously resistant to treatment.

Anthracenes↗
PubMed1985

Malignant hemangiopericytoma of the ovary.

Tumors originating from the blood vessels seldom occur in the ovaries, and primary hemangiopericytoma localized to the ovaries has not previously been described. In the case reported here a bilateral ovarian tumor was found, with one metastasis to the terminal ileum. It was not possible to perform a radical operation, and the patient was after-treated with external irradiation therapy and chemotherapy. For 9 1/2 months the tumor receded, whereafter it appeared to be stationary for 13 months, to the death of the patient. At autopsy the tumor was in evident regression and there were no signs of metastases.

Female↗
PubMed1985

Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.

A bioavailability study was performed with a pill containing microcrystalline 8-MOP and a soft gelatine capsule containing dissolved 8-MOP in 35 patients receiving PUVA treatment. Peak plasma levels were almost doubled after ingestion of the capsule preparation in comparison with those recorded from the pill takers. The pharmaceutical formulation of 8-MOP preparations is of decisive importance for the bioavailability of the drug. Variations in degree of absorption from different 8-MOP preparations and the existence of a metabolic first-pass effect probably explain the great inter-patient variability in therapeutic response. It is therefore advisable to individualize the dose of 8-MOP, primarily in slow responders, with the aim of obtaining a faster clearance but also to reduce the amount of UVA light involved.

Biological Availability↗
PubMed1981

Severe cervical dysplasia. Control by biopsies or primary conization? A comparative study.

During the period 1967-75 severe cervical dysplasia was diagnosed in 87 consecutive cases by means of colposcopically directed biopsies of the portio and by cervical curettage. Thirty-eight of the patients were treated, 3-6 weeks after diagnostic biopsy, by conization (conization group) and subsequently followed with smears and colposcopy. The remaining 49 patients (the biopsy group) were followed up at regular intervals by colposcopically directed biopsies of the portio and cervical curettage. The follow-up period for all 87 patients ranged from 9 to 106 months, mean 47.6 months. The groups were comparable with respect to the most important epidemiological factors. During the follow-up period progression to carcinoma in situ and to microinvasive carcinoma was found in 57.1% of the biopsy group but in 0% of the conization group. Of the whole material, 69 patients had conization (the 38 patients of the conization group plus 31 of the biopsy group). In 3 cases (4.35%) the cone diagnosis was 1 grade more serious than the biopsy diagnosis. The mean transit time of progression from severe dysplasia to CIS/MIC was 12-15 months. It is concluded that severe dysplasia is a rapidly progressing state which can be safely diagnosed by colposcopically directed biopsies of the portio and cervical curettage and effectively treated by conization. In view of the fact that not less than 32.7% of the cases with severe dysplasia in the biopsy group regressed during follow-up, we recommend that the diagnosis be established by portio biopsies and cervical curettage, twice with an interval of 3 months to restrict the number of superfluous conizations.

Biopsy↗